| Biomarker ID | 1772 |
| PMID | 30334974 |
| Year | 2018 |
| Biomarker | miR-141 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated in Bone Metastasis |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 100 patients were analysed for the study. 43 patients had PCa and 57 had benign prostatic hyperplasia group (BPH) |
| Senstivity | NA |
| Specificity | Full Dataset: 89.5%; PSA range 4 to 10ng/mL: 48.6% |
| AUC | Full Dataset: 0.625 (95% CI: 0.511-0.739); PSA range 4 to 10ng/mL: 0.621 (95% CI: 0.503-0.739) |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | miR-141 cutoff: 104.45; PSA range 4 to 10ng/mL: 20.6 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |